eXoZymes (EXOZ) Competitors $11.96 +1.39 (+13.15%) As of 09/5/2025 02:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock EXOZ vs. CADL, ALT, LRMR, AMRN, DMAC, FHTX, DRUG, OCGN, FDMT, and DSGNShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Candel Therapeutics (CADL), Altimmune (ALT), Larimar Therapeutics (LRMR), Amarin (AMRN), DiaMedica Therapeutics (DMAC), Foghorn Therapeutics (FHTX), Bright Minds Biosciences (DRUG), Ocugen (OCGN), 4D Molecular Therapeutics (FDMT), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Candel Therapeutics Altimmune Larimar Therapeutics Amarin DiaMedica Therapeutics Foghorn Therapeutics Bright Minds Biosciences Ocugen 4D Molecular Therapeutics Design Therapeutics eXoZymes (NASDAQ:EXOZ) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment. Do insiders and institutionals believe in EXOZ or CADL? 13.9% of Candel Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, EXOZ or CADL? eXoZymes has higher earnings, but lower revenue than Candel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymesN/AN/A-$5.86MN/AN/ACandel Therapeutics$120K2,287.50-$55.18M-$0.69-7.25 Does the media refer more to EXOZ or CADL? In the previous week, Candel Therapeutics had 14 more articles in the media than eXoZymes. MarketBeat recorded 14 mentions for Candel Therapeutics and 0 mentions for eXoZymes. Candel Therapeutics' average media sentiment score of 0.34 beat eXoZymes' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment eXoZymes Neutral Candel Therapeutics Neutral Do analysts rate EXOZ or CADL? Candel Therapeutics has a consensus price target of $20.00, indicating a potential upside of 300.00%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Candel Therapeutics is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Candel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is EXOZ or CADL more profitable? Candel Therapeutics' return on equity of -41.00% beat eXoZymes' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A -134.50% -81.63% Candel Therapeutics N/A -41.00%-26.81% SummaryCandel Therapeutics beats eXoZymes on 10 of the 12 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.31M$3.18B$5.83B$9.93BDividend YieldN/A2.26%6.70%4.52%P/E RatioN/A21.1076.1526.11Price / SalesN/A471.22564.25189.88Price / CashN/A45.7236.9959.28Price / Book9.579.8711.486.09Net Income-$5.86M-$53.42M$3.29B$266.51M7 Day Performance23.30%2.93%1.27%0.46%1 Month Performance19.48%9.85%7.94%4.59%1 Year PerformanceN/A15.74%62.94%26.04% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$11.96+13.2%N/AN/A$100.31MN/A0.0029Gap UpHigh Trading VolumeCADLCandel Therapeutics2.3062 of 5 stars$5.82-1.5%$22.00+278.0%-20.8%$324.43M$120K-8.4360News CoverageAnalyst DowngradeALTAltimmune2.7313 of 5 stars$3.71+1.1%$17.40+369.0%-40.8%$323.90M$20K-3.1450Gap UpLRMRLarimar Therapeutics3.5591 of 5 stars$3.91+0.3%$18.43+371.3%-55.7%$322.83MN/A-2.5130Positive NewsAnalyst RevisionAMRNAmarin0.6904 of 5 stars$15.40-0.5%$12.00-22.1%+25.7%$320.34M$228.61M-4.20360Gap DownDMACDiaMedica Therapeutics2.1592 of 5 stars$5.87-1.8%$12.33+110.1%+59.5%$309.10MN/A-8.5120Trending NewsAnalyst DowngradeInsider TradeFHTXFoghorn Therapeutics2.6847 of 5 stars$5.01-7.4%$10.67+112.9%-28.6%$305.83M$22.60M-4.21120Positive NewsDRUGBright Minds Biosciences2.83 of 5 stars$42.63-1.7%$83.25+95.3%+3,449.6%$305.43MN/A-45.84N/ANews CoverageOCGNOcugen1.5118 of 5 stars$1.05+1.0%$6.00+471.4%-12.7%$304M$4.05M-5.2580News CoverageFDMT4D Molecular Therapeutics2.9608 of 5 stars$6.18-4.3%$30.40+391.9%-53.1%$301.70M$40K-1.75120News CoverageDSGNDesign Therapeutics0.3303 of 5 stars$5.64+6.6%N/A+36.9%$301.26MN/A-5.0440News CoveragePositive News Related Companies and Tools Related Companies Candel Therapeutics Competitors Altimmune Competitors Larimar Therapeutics Competitors Amarin Competitors DiaMedica Therapeutics Competitors Foghorn Therapeutics Competitors Bright Minds Biosciences Competitors Ocugen Competitors 4D Molecular Therapeutics Competitors Design Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
